Validation of the MAAPE Score for Predicting Clinical Outcomes in Hepatocellular Carcinoma Treated With Selective Internal Radiation Therapy
- 11 November 2026
- journal article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Abstract
Background: Selective internal radiation therapy (SIRT) is an established treatment option for hepatocellular carcinoma (HCC); however, patient selection remains challenging. The MAAPE score (MELD, Albumin, AFP, PVTT, ECOG) was recently developed as a prognostic tool. This study aimed to provide an independent, single‐centre external validation of the MAAPE score in predicting clinical outcomes for patients treated with Yttrium‐90 SIRT. Methods: A retrospective analysis of patients with HCC treated with SIRT at a tertiary centre in Australia between 2012 and 2024 was performed. All patients received SIRT as first‐line treatment. Patients were stratified into Good, Average, and Poor prognosis groups based on their pre‐treatment MAAPE score. Tumour response and survival outcomes at 12 months were assessed as endpoints. Statistical analysis was performed using Kendall's rank correlation, Mann–Whitney tests, and Fisher's exact tests. Results: A total of 64 patients were included, of whom 62 were evaluable for 12‐month survival. Patients were stratified into Good ( n = 18; 28.1%), Average ( n = 29; 45.3%), and Poor ( n = 17; 26.6%) prognosis groups. The MAAPE score demonstrated a significant correlation with 12‐month survival ( p = 0.008) and tumour response ( p = 0.030). Patients in the Good prognosis group achieved an 88.2% survival rate at 12 months, compared to 62.1% and 43.8% for the Average and Poor groups respectively. While correlations were statistically significant, pairwise comparisons between prognosis groups were only significant when comparing Good and Poor ( p = 0.010 for 12‐month survival and p = 0.046 for tumour response). Conclusion: In this small single‐centre cohort, the MAAPE score identified patients with the most and least favourable 12‐month outcomes. It did not separate the adjacent prognosis groups from each other. These findings support the score at the extremes of risk, but they are preliminary. Larger prospective multicentre studies are required to assess the value of this score in personalised patient management.This publication has 18 references indexed in Scilit:
- BCLC strategy for prognosis prediction and treatment recommendations: The 2026 updateJournal of Hepatology, 2025
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Diagnostic Criteria and LI‐RADS for Hepatocellular CarcinomaClinical Liver Disease, 2021
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasionJournal of Hepatology, 2018
- Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experienceHepatology, 2017
- Comparison Between Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Assessing the Prognosis of Hepatocellular Carcinoma After Stereotactic Ablative Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 studyHepatology, 2012
- Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluationHepatology, 2011
- Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein ThrombosisJournal of Vascular and Interventional Radiology, 2010